CLARISCAN 376.9 mg/mL (Gadoterate Meglumine INJECTION, SOLUTION) 376.9 mg/mL

Clariscan 376.9 mg/mL is a gadoterate meglumine injection used for contrast enhancement in MRI scans. This solution aids in improving image clarity for better diagnostic evaluation.

Strength

376.9 mg/mL

Pack Size

10 VIAL, GLASS in 1 BOX (0407-2943-02) / 15 mL in 1 VIAL, GLASS

Manufacturer / TM Owner

GE Healthcare

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Clariscan 376.9 mg/mL is primarily used as a contrast agent in magnetic resonance imaging (MRI). It helps to enhance the visibility of certain tissues and structures, making it easier for healthcare professionals to diagnose and monitor various conditions. This injection is administered intravenously to improve the quality of MRI images, aiding in the detection of abnormalities.

Side Effects

When administered, Clariscan 376.9 mg/mL works by temporarily altering the magnetic properties of the tissues it highlights. This can result in clearer and more detailed MRI images, allowing for better visualization of the body's internal structures. The effects are typically short-lived, as the contrast agent is naturally eliminated from the body.

Precautions & Warnings

Clariscan 376.9 mg/mL should be used with caution in individuals with known allergies to gadoterate meglumine or similar contrast agents. It is important to inform healthcare providers about any pre-existing conditions, especially kidney problems, as this may affect the safety and effectiveness of the injection. Always follow the advice of a healthcare professional regarding the use of this contrast agent.

Avoid Interactions

Clariscan 376.9 mg/mL may interact with certain medications or medical conditions. It is important to disclose all current medications and health conditions to your healthcare provider before administration. Specific interactions with other drugs are not well-documented, but caution is advised when using this contrast agent in conjunction with other intravenous treatments.

References

Frequently Asked Questions

Clariscan 376.9 mg/mL is used as a contrast agent to enhance the visibility of tissues and structures during MRI scans.

Clariscan 376.9 mg/mL is administered intravenously by a healthcare professional during an MRI procedure.

Clariscan 376.9 mg/mL temporarily alters the magnetic properties of tissues, enhancing the clarity of MRI images.

Individuals with allergies to gadoterate meglumine or kidney problems should use Clariscan 376.9 mg/mL with caution.

It is important to inform your healthcare provider about all current medications to check for potential interactions.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.